152 related articles for article (PubMed ID: 15117573)
1. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
2. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
Law SL; Huang KJ; Chiang CH
J Control Release; 2000 Jan; 63(1-2):135-40. PubMed ID: 10640587
[TBL] [Abstract][Full Text] [Related]
3. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
Liu H; Pan WS; Tang R; Luo SD
Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
[TBL] [Abstract][Full Text] [Related]
4. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
5. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
[TBL] [Abstract][Full Text] [Related]
6. Intraocular penetration of topically administered acyclovir.
Kitagawa K; Fukuda M; Sasaki K
Lens Eye Toxic Res; 1989; 6(1-2):365-73. PubMed ID: 2488028
[TBL] [Abstract][Full Text] [Related]
7. [Effects of honey to acyclovir in the rabbit eye transport kinetics].
He Q; Wang S; Zhang X; Zhang J; Jiang Y; Xu J
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(19):2723-6. PubMed ID: 22242438
[TBL] [Abstract][Full Text] [Related]
8. Improved permeability of acyclovir: optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay.
Naderkhani E; Erber A; Škalko-Basnet N; Flaten GE
J Pharm Sci; 2014 Feb; 103(2):661-8. PubMed ID: 24395733
[TBL] [Abstract][Full Text] [Related]
9. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
10. Failure of topical acyclovir in ointment to penetrate human skin.
Freeman DJ; Sheth NV; Spruance SL
Antimicrob Agents Chemother; 1986 May; 29(5):730-2. PubMed ID: 3729337
[TBL] [Abstract][Full Text] [Related]
11. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
12. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
Shukla C; Friden P; Juluru R; Stagni G
J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of acyclovir in rabbit skin after i.v.-bolus, ointment, and iontophoretic administrations.
Stagni G; Ali ME; Weng D
Int J Pharm; 2004 Apr; 274(1-2):201-11. PubMed ID: 15072796
[TBL] [Abstract][Full Text] [Related]
14. Liposomes as a potential ocular delivery system of distamycin A.
Chetoni P; Monti D; Tampucci S; Matteoli B; Ceccherini-Nelli L; Subissi A; Burgalassi S
Int J Pharm; 2015 Aug; 492(1-2):120-6. PubMed ID: 26183332
[TBL] [Abstract][Full Text] [Related]
15. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
[TBL] [Abstract][Full Text] [Related]
16. Preclinical toxicology studies with acyclovir: ophthalmic and cutaneous tests.
Tucker WE; Johnston RE; Macklin AW; Szot RJ; Elion GB; de Miranda P; Szczech GM
Fundam Appl Toxicol; 1983; 3(6):569-72. PubMed ID: 6662298
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
18. Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.
Abla N; Naik A; Guy RH; Kalia YN
Pharm Res; 2006 Aug; 23(8):1842-9. PubMed ID: 16850271
[TBL] [Abstract][Full Text] [Related]
19. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.
Spruance SL; Freeman DJ; Sheth NV
Antimicrob Agents Chemother; 1985 Jul; 28(1):103-6. PubMed ID: 4037770
[TBL] [Abstract][Full Text] [Related]
20. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study.
El-Gizawy SA; El-Maghraby GM; Hedaya AA
Pharm Dev Technol; 2019 Dec; 24(10):1299-1307. PubMed ID: 31507245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
